Lumakras Treatment Journey: What to Expect Before, During, and After Therapy
Starting a new cancer treatment can come with a lot of questions, especially when there are different tests, appointments, medicines, and follow-up steps involved. If you or a loved one are beginning treatment with LUMAKRAS®, understanding what the journey may look like before, during, and after therapy can help make the process feel a little more familiar and manageable.
What Is Lumakras?
LUMAKRAS® (sotorasib) is a targeted cancer medicine designed to act on a specific mutation called KRAS G12C. Sotorasib is a KRAS inhibitor that works by targeting the abnormal KRAS protein linked with certain cancers.1
What Is Lumakras Used For?
LUMAKRAS is used for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) identified through an FDA-approved test. It is used in patients who have already received at least one prior systemic therapy.1,2
How Does Lumakras Work?
KRAS is a protein involved in important cell signaling pathways linked with cell growth, survival, and proliferation. In healthy cells, KRAS switches between an active and inactive state to help control normal cell function.
In some cancers, a mutation called KRAS G12C changes how this protein behaves. This mutation can keep KRAS in an overactive state, which may lead to uncontrolled cancer cell growth. LUMAKRAS works by binding specifically to the KRAS G12C protein and trapping it in its inactive state. This helps block abnormal KRAS signaling linked with tumor growth.1,2
What Is KRAS G12C-Mutated Lung Cancer?
KRAS G12C-mutated lung cancer is a type of non-small cell lung cancer where cancer cells carry a specific mutation called KRAS p.G12C. This mutation is present in around 12–15% of non-small cell lung cancers.
The KRAS G12C mutation can lead to abnormal activation of pathways involved in cancer growth and survival. Because of this, KRAS G12C has become an important target in lung cancer treatment research.1,2
Why KRAS G12C Testing Matters Before Lumakras
Before starting LUMAKRAS®, doctors first confirm whether the cancer has the KRAS G12C mutation using an FDA-approved test. This testing is important because LUMAKRAS is specifically used for cancers carrying this mutation. Identifying KRAS G12C status helps guide treatment planning and determine whether LUMAKRAS may be an appropriate treatment option.1,2
Who May Be Eligible For Lumakras?
LUMAKRAS® may be considered for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has a KRAS G12C mutation confirmed through an FDA-approved test.
It is used in patients who have already received at least one prior systemic therapy. Testing for the KRAS G12C mutation is important because LUMAKRAS specifically targets cancers carrying this mutation.1,2
Lumakras Dosage
- What Patients Should Know
The recommended dosage of LUMAKRAS® is 960 mg taken orally once daily. This can be taken as three 320 mg tablets or eight 120 mg tablets. Treatment is generally continued until disease progression or unacceptable toxicity.2
- How To Take Lumakras Safely
Patients are advised to take LUMAKRAS at the same time each day, with or without food. The tablets should be swallowed whole and should not be chewed, crushed, or split.
If a dose is missed by more than 6 hours, patients should skip the missed dose and take the next dose the following day as prescribed. Two doses should not be taken together to make up for a missed dose. If vomiting occurs after taking LUMAKRAS, an extra dose should not be taken, and the next dose should be taken the next day as scheduled.2
For patients who have difficulty swallowing tablets, LUMAKRAS may be dispersed in 120 mL (4 ounces) of non-carbonated room-temperature water. The tablets should not be crushed. The mixture should be stirred for around 3 minutes until the tablets break into small pieces and then consumed immediately or within 2 hours. The container should then be rinsed with another 120 mL of water, which should also be consumed.2
Common Side Effects Of Lumakras
Several side effects were reported during clinical trials of LUMAKRAS® (sotorasib). The most commonly reported side effects included:2
- Diarrhea – 42%
- Musculoskeletal pain – 35%
- Nausea – 26%
- Fatigue – 26%
- Hepatotoxicity (liver-related side effects) – 25%
- Cough – 20%
Serious adverse reactions occurred in 50% of patients receiving sotorasib. The most frequently reported serious side effects included:2
- Pneumonia – 8%
- Hepatotoxicity – 3%
- Diarrhea – 2%
Common laboratory abnormalities seen in 30% or more patients included:2
- Increased AST/ALT liver enzymes
- Increased alkaline phosphatase
- Decreased lymphocytes
- Decreased hemoglobin
- Decreased calcium
Serious Side Effects And Warning Signs
- Liver Problems And Lab Monitoring During LumakrasLiver Problems And Lab Monitoring During Lumakras
During treatment with LUMAKRAS®, doctors may regularly monitor patients for certain side effects, especially related to the liver and lungs.2
Liver-related side effects (hepatotoxicity) were reported in some patients during the CodeBreaK 100 study. Increased liver enzymes such as ALT and AST were seen in 18% of patients, including some Grade 3 and Grade 4 cases. Because of this, patients may undergo regular liver function tests before starting treatment, every 3 weeks during the first 3 months, and then monthly or as clinically needed.2
- Lung Inflammation Risks Patients Should Know About
LUMAKRAS may sometimes cause interstitial lung disease (ILD)/pneumonitis, including rare serious or fatal cases. Patients are advised to watch for new or worsening breathing-related symptoms such as:2
- Shortness of breath (dyspnea)
- Cough
- Fever
If serious side effects are suspected, doctors may temporarily stop treatment, adjust the dose, or permanently discontinue LUMAKRAS depending on severity.
Can Lumakras Interact With Other Medicines?
Yes, LUMAKRAS® may interact with certain medicines and affect how they work in the body.2
- LUMAKRAS can affect medicines called CYP3A4 substrates, which may lower the effectiveness of those medicines.
- It may also affect P-glycoprotein (P-gp) substrates, which could increase the risk of side effects linked with those medicines.
- LUMAKRAS can additionally interact with Breast Cancer Resistance Protein (BCRP) substrates, which may increase the chances of adverse reactions.
Because of this, patients are advised to tell their healthcare provider about all prescription medicines, over-the-counter medicines, vitamins, and supplements they are taking before starting LUMAKRAS.2
What To Expect After Lumakras Treatment Or Follow-Up
After starting LUMAKRAS®, patients may continue having regular follow-up visits, scans, and monitoring to check how the treatment is working and to manage any side effects.2
In the CodeBreaK 100 study, patients received LUMAKRAS 960 mg once daily until disease progression or unacceptable toxicity. The major measures studied included:2
- Objective Response Rate (ORR) – 36%
- Complete response – 2%
- Partial response – 35%
- Median duration of response (DOR) – 10 months
- 58% of responding patients had a response lasting 6 months or longer
- Patients may also continue follow-up blood tests and monitoring for symptoms during treatment, especially for side effects involving the liver or lungs.2
What To Ask Your Doctor Before Starting Lumakras
Before starting LUMAKRAS®, it can help to have an open conversation with your doctor about the treatment plan, follow-up process, and what to expect during therapy.
Some questions patients may want to ask include:
- Why is LUMAKRAS being recommended for me?
- What tests are needed before starting treatment?
- How should I take LUMAKRAS each day?
- What side effects should I watch for?
- Will I need regular blood tests or scans?
- What should I do if I miss a dose?
- Can LUMAKRAS interact with other medicines or supplements I take?
- How often will follow-up visits be needed?
- What symptoms should be reported immediately?
- Who should I contact if I have concerns during treatment?
Final Thoughts
LUMAKRAS® is a targeted treatment option developed for certain patients with KRAS G12C-mutated non-small cell lung cancer. Understanding KRAS testing, dosage, side effects, monitoring, and follow-up care may help patients and caregivers feel more informed and prepared during treatment.¹˒²
FAQs
- What is Lumakras used for?
LUMAKRAS is used for adults with KRAS G12C-mutated locally advanced or metastatic NSCLC after prior systemic therapy.²
- Is Lumakras chemotherapy?
No, LUMAKRAS is a targeted KRAS G12C inhibitor.¹
- How does Lumakras work?
LUMAKRAS works by binding to KRAS G12C and keeping it in an inactive state to block abnormal signaling.¹
- What is the usual dosage of Lumakras?
The recommended dosage is 960 mg taken orally once daily.²
- What serious side effects should I watch for?
Patients are advised to watch for liver-related side effects and breathing symptoms linked with ILD/pneumonitis.²
References
- Ganguly A, Yoo E. Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer. Trends Pharmacol Sci. 2022;43(6):536-537. doi:10.1016/j.tips.2022.03.011
- Lumakras Prescribing Information
Note:
The information provided is for education purpose only and is subjected to prescribing information of the drug and the guidance of your treating physician. Always consult your health care provider before making any medical decision for starting your treatment.
Disclaimer:
Rx4U procures prescribed medicines directly from manufacturers or authorized distributors. It does not claim ownership of any trademarks and complies with the provisions of the Trademark Act, 1999, particularly Sections 30 and 30(1) concerning ‘Fair Use’. It solely facilitates access to new launches through named patient import.
